4.5 Article

Thirty-two years' experience of treating fulminant hepatitis in a Japanese single center

Journal

HEPATOLOGY RESEARCH
Volume 53, Issue 4, Pages 357-369

Publisher

WILEY
DOI: 10.1111/hepr.13873

Keywords

acute liver failure; autoimmune hepatitis; etiology; fulminant hepatitis; survival

Ask authors/readers for more resources

The prognosis of patients with fulminant hepatitis and late-onset hepatic failure in Japan has not improved over the past 32 years, despite advancements in clinical management and liver transplantation. The increasing proportion of patients with poor prognosis and difficult-to-treat etiologies, as well as the aging population, may contribute to this lack of improvement.
AimThe prognosis of patients with acute liver failure has improved dramatically in the past three decades due to advances in medical critical care and use of liver transplantation (LT) in Western countries, where the etiology of acute liver failure is different from that in Japan. We analyzed patients with fulminant hepatitis (FH) and late-onset hepatic failure (LOHF) admitted to our unit over a 32-year period to clarify the nature of Japanese patients with FH and LOHF. MethodsA total of 137 Japanese patients with FH and LOHF between 1986 and 2017 were analyzed for etiologies, disease types, treatment protocols, and outcome. ResultsOf 137 patients, 124 were FH (53 acute type and 71 subacute type) and 13 LOHF. The major etiology was due to viral infections in 48% of patients. A total of 23.4% of patients recovered without LT, 7.3% received LT, and 69.3% died without LT. The number of patients showed rise and fall without an evident decrease during the period. Patients with autoimmune hepatitis increased after the establishment of autoimmune hepatitis criteria in 1999 (p < 0.001), and that with indeterminate cause decreased (p < 0.01). The mean age was older in the last decade than in the first decade (p = 0.036). Spontaneous and overall survival rates were not different during the period. ConclusionsThe prognosis of our patients with FH and LOHF has not improved, probably because of aging and the increasing proportion of etiologies with poor prognosis and difficult-to-treat patients without response to medications regardless of advancement of clinical management, including artificial liver support devices and LT.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available